• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

寡核苷酸的递送:脂质偶联的效率与临床结果

Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome.

作者信息

Tran Phuc, Weldemichael Tsigereda, Liu Zhichao, Li Hong-Yu

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA.

出版信息

Pharmaceutics. 2022 Feb 1;14(2):342. doi: 10.3390/pharmaceutics14020342.

DOI:10.3390/pharmaceutics14020342
PMID:35214074
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8879684/
Abstract

Oligonucleotides have shifted drug discovery into a new paradigm due to their ability to silence the genes and inhibit protein translation. Importantly, they can drug the un-druggable targets from the conventional small-molecule perspective. Unfortunately, poor cellular permeability and susceptibility to nuclease degradation remain as major hurdles for the development of oligonucleotide therapeutic agents. Studies of safe and effective delivery technique with lipid bioconjugates gains attention to resolve these issues. Our review article summarizes the physicochemical effect of well-studied hydrophobic moieties to enhance the cellular entry of oligonucleotides. The structural impacts of fatty acids, cholesterol, tocopherol, and squalene on cellular internalization and membrane penetration in vitro and in vivo were discussed first. The crucial assays for delivery evaluation within this section were analyzed sequentially. Next, we provided a few successful examples of lipid-conjugated oligonucleotides advanced into clinical studies for treating patients with different medical backgrounds. Finally, we pinpointed current limitations and outlooks in this research field along with opportunities to explore new modifications and efficacy studies.

摘要

由于能够使基因沉默并抑制蛋白质翻译,寡核苷酸已将药物发现带入了一个新的范式。重要的是,从传统小分子的角度来看,它们可以作用于难以成药的靶点。不幸的是,较差的细胞通透性和对核酸酶降解的敏感性仍然是寡核苷酸治疗剂开发的主要障碍。对脂质生物共轭物安全有效的递送技术的研究受到关注,以解决这些问题。我们的综述文章总结了经过充分研究的疏水部分对增强寡核苷酸细胞摄取的物理化学作用。首先讨论了脂肪酸、胆固醇、生育酚和角鲨烯在体外和体内对细胞内化和膜穿透的结构影响。依次分析了本节中用于递送评估的关键试验。接下来,我们提供了一些脂质共轭寡核苷酸进入临床研究以治疗不同医学背景患者的成功例子。最后,我们指出了该研究领域当前的局限性和前景,以及探索新修饰和疗效研究的机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9471/8879684/3db3c3b41ecb/pharmaceutics-14-00342-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9471/8879684/63be99c392bb/pharmaceutics-14-00342-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9471/8879684/8069cd0aafe6/pharmaceutics-14-00342-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9471/8879684/f6cc10c1254c/pharmaceutics-14-00342-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9471/8879684/07b0e5a31976/pharmaceutics-14-00342-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9471/8879684/ee8a0b6a6df5/pharmaceutics-14-00342-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9471/8879684/3db3c3b41ecb/pharmaceutics-14-00342-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9471/8879684/63be99c392bb/pharmaceutics-14-00342-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9471/8879684/8069cd0aafe6/pharmaceutics-14-00342-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9471/8879684/f6cc10c1254c/pharmaceutics-14-00342-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9471/8879684/07b0e5a31976/pharmaceutics-14-00342-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9471/8879684/ee8a0b6a6df5/pharmaceutics-14-00342-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9471/8879684/3db3c3b41ecb/pharmaceutics-14-00342-g006.jpg

相似文献

1
Delivery of Oligonucleotides: Efficiency with Lipid Conjugation and Clinical Outcome.寡核苷酸的递送:脂质偶联的效率与临床结果
Pharmaceutics. 2022 Feb 1;14(2):342. doi: 10.3390/pharmaceutics14020342.
2
Lipid conjugated oligonucleotides: a useful strategy for delivery.脂质偶联寡核苷酸:一种有用的递药策略。
Bioconjug Chem. 2012 Jun 20;23(6):1091-104. doi: 10.1021/bc200422w. Epub 2012 Mar 15.
3
Opportunities and challenges of fatty acid conjugated therapeutics.脂肪酸共轭治疗剂的机遇与挑战。
Chem Phys Lipids. 2021 May;236:105053. doi: 10.1016/j.chemphyslip.2021.105053. Epub 2021 Jan 20.
4
The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery.辅助脂质在用于寡核苷酸递送的脂质纳米颗粒(LNP)中的作用。
Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):129-137. doi: 10.1016/j.addr.2016.01.022. Epub 2016 Feb 18.
5
Hyaluronan-based delivery of therapeutic oligonucleotides for treatment of human diseases.基于透明质酸的治疗性寡核苷酸递药系统治疗人类疾病。
Expert Opin Drug Deliv. 2019 Jun;16(6):621-637. doi: 10.1080/17425247.2019.1617693. Epub 2019 May 20.
6
Double-tailed lipid modification as a promising candidate for oligonucleotide delivery in mammalian cells.双尾脂质修饰作为哺乳动物细胞中寡核苷酸递送的一个有前景的候选方法。
Biochim Biophys Acta. 2013 Oct;1830(10):4872-84. doi: 10.1016/j.bbagen.2013.06.013. Epub 2013 Jun 23.
7
Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.脂质纳米颗粒技术在 siRNA 治疗药物临床转化中的应用
Acc Chem Res. 2019 Sep 17;52(9):2435-2444. doi: 10.1021/acs.accounts.9b00368. Epub 2019 Aug 9.
8
Oligonucleotide conjugates for therapeutic applications.用于治疗应用的寡核苷酸缀合物。
Ther Deliv. 2013 Jul;4(7):791-809. doi: 10.4155/tde.13.47.
9
Evaluation of Floxuridine Oligonucleotide Conjugates Carrying Potential Enhancers of Cellular Uptake.携带细胞摄取潜在增强剂的氟尿苷寡核苷酸缀合物的评估。
Int J Mol Sci. 2021 May 26;22(11):5678. doi: 10.3390/ijms22115678.
10
Liver as a target for oligonucleotide therapeutics.肝脏作为寡核苷酸治疗药物的靶标。
J Hepatol. 2013 Dec;59(6):1354-9. doi: 10.1016/j.jhep.2013.05.045. Epub 2013 Jun 12.

引用本文的文献

1
Integrative Approaches to Myopathies and Muscular Dystrophies: Molecular Mechanisms, Diagnostics, and Future Therapies.肌病和肌肉萎缩症的综合治疗方法:分子机制、诊断及未来疗法
Int J Mol Sci. 2025 Aug 18;26(16):7972. doi: 10.3390/ijms26167972.
2
Delivery strategies for RNA-targeting therapeutic nucleic acids and RNA-based vaccines against respiratory RNA viruses: IAV, SARS-CoV-2, RSV.针对呼吸道RNA病毒(甲型流感病毒、严重急性呼吸综合征冠状病毒2、呼吸道合胞病毒)的RNA靶向治疗性核酸和基于RNA的疫苗的递送策略
Mol Ther Nucleic Acids. 2025 May 20;36(3):102572. doi: 10.1016/j.omtn.2025.102572. eCollection 2025 Sep 9.
3
Schwann Cells in Neuromuscular Disorders: A Spotlight on Amyotrophic Lateral Sclerosis.

本文引用的文献

1
Lipid-oligonucleotide conjugates for bioapplications.用于生物应用的脂质 - 寡核苷酸缀合物。
Natl Sci Rev. 2020 Jul 9;7(12):1933-1953. doi: 10.1093/nsr/nwaa161. eCollection 2020 Dec.
2
Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model.基于纳米颗粒的寡核苷酸在癌症中的递送:斑马鱼作为动物模型的作用
Pharmaceutics. 2021 Jul 21;13(8):1106. doi: 10.3390/pharmaceutics13081106.
3
Lipids and Lipid Derivatives for RNA Delivery.用于 RNA 递送的脂质和脂质衍生物。
神经肌肉疾病中的施万细胞:聚焦肌萎缩侧索硬化症
Cells. 2025 Jan 3;14(1):47. doi: 10.3390/cells14010047.
4
Reconfigurable Amphiphilic DNA Nanotweezer for Targeted Delivery of Therapeutic Oligonucleotides.用于靶向递送治疗性寡核苷酸的可重构两亲性DNA纳米镊子
ACS Cent Sci. 2024 Dec 5;10(12):2338-2345. doi: 10.1021/acscentsci.4c01152. eCollection 2024 Dec 25.
5
Evolution of antisense oligonucleotides: navigating nucleic acid chemistry and delivery challenges.反义寡核苷酸的发展:应对核酸化学及递送挑战
Expert Opin Drug Discov. 2025 Jan;20(1):63-80. doi: 10.1080/17460441.2024.2440095. Epub 2024 Dec 17.
6
Thiol-Specific Linkers for the Synthesis of Oligonucleotide Conjugates via Metal-Free Thiol-Ene Click Reaction.用于通过无金属硫醇-烯点击反应合成寡核苷酸缀合物的硫醇特异性连接子。
Bioconjug Chem. 2024 Sep 12;35(10):1553-67. doi: 10.1021/acs.bioconjchem.4c00336.
7
Limb Girdle Muscular Dystrophy Type 2B (LGMD2B): Diagnosis and Therapeutic Possibilities.肢带型肌营养不良 2B 型(LGMD2B):诊断与治疗的可能。
Int J Mol Sci. 2024 May 21;25(11):5572. doi: 10.3390/ijms25115572.
8
Splice-Modulating Antisense Oligonucleotides as Therapeutics for Inherited Metabolic Diseases.剪接调节反义寡核苷酸作为遗传性代谢疾病的治疗方法。
BioDrugs. 2024 Mar;38(2):177-203. doi: 10.1007/s40259-024-00644-7. Epub 2024 Jan 22.
9
Self-delivering, chemically modified CRISPR RNAs for AAV co-delivery and genome editing in vivo.自递呈的、化学修饰的 CRISPR RNA 用于 AAV 共递送和体内基因组编辑。
Nucleic Acids Res. 2024 Jan 25;52(2):977-997. doi: 10.1093/nar/gkad1125.
10
Fork- and Comb-like Lipophilic Structures: Different Chemical Approaches to the Synthesis of Oligonucleotides with Multiple Dodecyl Residues.叉状和梳状亲脂结构:用多种十二烷基残基合成寡核苷酸的不同化学方法。
Int J Mol Sci. 2023 Sep 27;24(19):14637. doi: 10.3390/ijms241914637.
Chem Rev. 2021 Oct 27;121(20):12181-12277. doi: 10.1021/acs.chemrev.1c00244. Epub 2021 Jul 19.
4
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability.mRNA-脂质纳米颗粒 COVID-19 疫苗:结构与稳定性。
Int J Pharm. 2021 May 15;601:120586. doi: 10.1016/j.ijpharm.2021.120586. Epub 2021 Apr 9.
5
Recent Advances in Oligonucleotide Therapeutics in Oncology.肿瘤学中寡核苷酸治疗的最新进展。
Int J Mol Sci. 2021 Mar 24;22(7):3295. doi: 10.3390/ijms22073295.
6
Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles.二十二烷酸与 siRNA 的结合使它能够安全有效地递送到骨骼肌和心肌中。
Mol Ther. 2021 Apr 7;29(4):1382-1394. doi: 10.1016/j.ymthe.2020.12.023. Epub 2020 Dec 19.
7
Myostatin deficiency not only prevents muscle wasting but also improves survival in septic mice.肌肉生长抑制素缺乏不仅可以防止肌肉减少,还可以提高脓毒症小鼠的存活率。
Am J Physiol Endocrinol Metab. 2021 Jan 1;320(1):E150-E159. doi: 10.1152/ajpendo.00161.2020. Epub 2020 Dec 7.
8
The elusive promise of myostatin inhibition for muscular dystrophy.肌抑素抑制治疗肌肉萎缩症的 elusive promise。
Curr Opin Neurol. 2020 Oct;33(5):621-628. doi: 10.1097/WCO.0000000000000853.
9
Myostatin Is a Quantifiable Biomarker for Monitoring Pharmaco-gene Therapy in Duchenne Muscular Dystrophy.肌生成抑制蛋白是监测杜氏肌营养不良症药物基因治疗的可量化生物标志物。
Mol Ther Methods Clin Dev. 2020 Jun 24;18:415-421. doi: 10.1016/j.omtm.2020.06.016. eCollection 2020 Sep 11.
10
Trimeric Small Interfering RNAs and Their Cholesterol-Containing Conjugates Exhibit Improved Accumulation in Tumors, but Dramatically Reduced Silencing Activity.三聚体小干扰 RNA 及其含胆固醇的缀合物在肿瘤中的蓄积得到改善,但沉默活性显著降低。
Molecules. 2020 Apr 18;25(8):1877. doi: 10.3390/molecules25081877.